Elfrida Benjamin
57Patents
20h-index
10Co-inventors
81Inventor score
Filing activity: Oct 14, 2005 → May 31, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8592362B2 | Method to predict response to pharmacological chaperone treatment of diseases | Physics | 53 | Active |
| US10076514B2 | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene | Human Necessities | 51 | Active |
| US10537564B2 | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene | Human Necessities | 50 | Active |
| US9095584B2 | Method to predict response to pharmacological chaperone treatment of diseases | Physics | 50 | Active |
| US10251873B2 | Methods of treating fabry patients having renal impairment | Human Necessities | 48 | Active |
| US10471053B2 | Methods of treating Fabry patients having renal impairment | Human Necessities | 48 | Active |
| US9545397B2 | Method to predict response to pharmacological chaperone treatment of diseases | Physics | 48 | Active |
| US10849889B2 | Methods of treating Fabry patients having renal impairment | Human Necessities | 37 | Active |
| US10857142B2 | Methods of treating Fabry patients having renal impairment | Human Necessities | 37 | Active |
| US10792279B2 | Methods of treating Fabry patients having renal impairment | Human Necessities | 37 | Active |
| US10799491B2 | Methods of treating Fabry patients having renal impairment | Human Necessities | 37 | Active |
| US10806727B2 | Methods of treating fabry patients having renal impairment | Human Necessities | 37 | Active |
| US10813921B2 | Method to predict response to pharmacological chaperone treatment of diseases | Physics | 37 | Active |
| US10849890B2 | Methods of treating Fabry patients having renal impairment | Human Necessities | 37 | Active |
| US10874655B2 | Methods of treating fabry patients having renal impairment | Human Necessities | 37 | Active |
| US10792278B2 | Methods of treating Fabry patients having renal impairment | Human Necessities | 37 | Active |
| US10857141B2 | Methods of treating Fabry patients having renal impairment | Human Necessities | 37 | Active |
| US10874656B2 | Methods of treating Fabry patients having renal impairment | Human Necessities | 37 | Active |
| US10874657B2 | Methods of treating Fabry patients having renal impairment | Human Necessities | 37 | Active |
| USRE48608E1 | Method to predict response to pharmacological chaperone treatment of diseases | General | 35 | Active |
| US11304940B2 | Methods of treating Fabry patients having renal impairment | Human Necessities | 8 | Active |
| US11426396B2 | Methods of treating Fabry patients having renal impairment | Human Necessities | 7 | Active |
| US11357765B1 | Methods of treating Fabry patients having renal impairment | Human Necessities | 6 | Active |
| US11234972B2 | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene | Human Necessities | 5 | Active |
| US11278539B2 | Methods of treating Fabry patients having renal impairment | Human Necessities | 4 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.